Real-World Effectiveness of Avelumab in First-Line Maintenance for Bladder Cancer

At ASCO GU 2025, Dr. Peter J. Goebell shared his insights from the AVENUE study, examining the real-world effectiveness and safety of avelumab as a first-line maintenance therapy for bladder cancer. He discussed treatment outcomes, patient management, and the comparison between clinical trial data and real-world results.